BridgeBio Pharma (BBIO) Assets (2018 - 2026)

BridgeBio Pharma's Assets history runs 9 years deep, the most recent figure standing at $1.4 billion for Q1 2026.

• In Q1 2026, Assets rose 55.5% year-over-year to $1.4 billion; the TTM figure through Mar 2026 stood at $1.4 billion (up 55.5% YoY), while the FY2025 annual figure was $936.0 million, up 1.82% from the prior year.
• Assets came in at $1.4 billion for Q1 2026 at BridgeBio Pharma, up from $936.0 million in the prior quarter.
• In the past five years, Assets ranged from a high of $1.4 billion in Q1 2026 to a low of $503.7 million in Q2 2023.
• A 5-year average of $814.9 million and a median of $813.1 million in 2022 frame the typical range for Assets.
• Across the five-year window, Assets tumbled 41.59% in 2023 and surged 68.26% in 2024, its largest moves.
• BridgeBio Pharma's Assets stood at $623.0 million in 2022, then fell by 12.3% to $546.4 million in 2023, then soared by 68.26% to $919.3 million in 2024, then gained by 1.82% to $936.0 million in 2025, then surged by 46.47% to $1.4 billion in 2026.
• According to Business Quant data, Assets over the past three periods registered $1.4 billion, $936.0 million, and $998.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison